Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223938 · ClinicalTrials.gov registry record · Phase 4
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
A Phase 4 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
NCT00223938 is a Phase 4 study that was terminated before completion, run by Sanofi. The registered enrollment target is 112 participants.
The verdict
NCT00223938, a Phase 4 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
Study Summary
This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin.
Interventions
- DRUG Oral Iron
- DRUG sodium ferric gluconate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2003-12-30 |
| Est. Completion | 2007-04-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223938
The ClinicalTrials.gov registry entry for NCT00223938 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral Iron is the first listed.
NCT00223938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00223938 about?
NCT00223938 is a clinical study titled "Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.". This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin.
What is the current status of trial NCT00223938?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2003-12-30. Estimated completion is 2007-04-27.
What interventions are being tested in trial NCT00223938?
The interventions under investigation include: Oral Iron (DRUG), sodium ferric gluconate (DRUG).
Who is sponsoring clinical trial NCT00223938?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.